Pletcher Brett A
Known title: EVP, Chief Legal OfficerCIK: 0001739307
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers. Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.
Transaction History
| CYTK | ▲ Buy | Grant | 33,140 | $0 | 8/30/2024 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 280 | $17K | 6/10/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 782 | — | 6/10/2022 | View on chart |
| GILD | ▼ Sell | Open Market | 3,634 | $212K | 3/11/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 2,593 | — | 3/10/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 3,130 | — | 3/10/2022 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 2,089 | $121K | 3/10/2022 | View on chart |
| GILD | ▲ Buy | Grant | 348 | $18K | 2/15/2022 | View on chart |
| GILD | ▼ Sell | Open Market | 1,691 | $108K | 2/9/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 2,727 | $0 | 2/6/2022 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 1,036 | $66K | 2/6/2022 | View on chart |
| GILD | ▼ Sell | Open Market | 14,061 | $964K | 2/1/2022 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 5,681 | $383K | 1/26/2022 | View on chart |
| GILD | ▲ Buy | Grant | 19,742 | $0 | 1/26/2022 | View on chart |
| GILD | ▲ Buy | Grant | 15,262 | $0 | 1/26/2022 | View on chart |
| GILD | ▲ Buy | Grant | 32 | $2K | 8/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Cytokinetics Launches ASPEN-HCM Real-World Study
Cytokinetics has initiated the ASPEN-HCM study to evaluate MYQORZO in real-world patients with symptomatic obstructive hypertrophic cardiomyopathy. The company also announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026. These clinical updates provide new data points for investors, while the stock currently trades near its 52-week low.
Cytokinetics Launches ASPEN-HCM Real-World Study. Cytokinetics has initiated the ASPEN-HCM study to evaluate MYQORZO in real-world patients with symptomatic obstructive hypertrophic cardiomyopathy. The company also announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026. These clinical updates provide new data points for investors, while the stock currently trades near its 52-week low.